Table 2.
Surgical and Oncologic Outcomes.
| Patient | Cytoreductive surgery | Surgical complications | Final Gleason score | Pathological stage | Surgical margin status | Postoperative PSA (ng/mL) | Postoperative ADT | Postoperative radiation | Follow-up (mo) | Follow-up continence | Follow-up PSA (ng/mL) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RARP + pelvic lymphadenectomy | – | 4+5 | pT3bN1 | Negative | 1.23 | – | Stereotactic radiation to 7th rib | 8 | Pad-free | 0.36 |
| 2 | RARP | – | 4+5 | pT3bNx | Negative | 0.77 | LHRH agonist + bicalutamide | Stereotactic radiation to pubic ramus (POPSTAR trial) | 21 | Pad-free | 0.44 |
| 3 | RARP+ pelvic lymphadenectomy | – | 5+4 | pT3bN0 | Focal positive margins at base, apex | 19.9 | LHRH agonist + bicalutamide | Stereotactic radiation to L3 vertebra | 21 | Pad-free | 4.7 |
| 4 | RARP + pelvic lymphadenectomy | – | 4+5 | pT3bN0 | Positive | < 0.1 | LHRH agonist | Adjuvant radiotherapy, subsequent stereotactic radiation to right iliac lesion (POPSTAR trial) | 36 | Pad-free | 0.1 |
| 5 | Pelvic exenteration | Colorectal anastomotic leak managed with defunctioning stoma | 4+3 | pT4N0 | N/A | 0.3 | Nil | Stereotactic radiation to new metastatic lesions 7 mo. Post-op (pelvic lymph node, ilium, rib) | 10 | Ileal conduit | 5.1 |
| 6 | RARP | Nil | 4+4 | pT2c | Negative | < 0.01 | LHRH agonist (ceased 2 mo. post- RARP) | Stereotactic radiation to three metastatic sites | 17 | Pad-free | 0.07 |
ADT, androgen-deprivation therapy; LHRH, luteinizing hormone-releasing hormone; N/A, not applicable; PSA, prostate-specific antigen; RARP, robot-assisted radical prostatectomy.